(Q33571347)

28 July 2017

The HALT polycystic kidney disease trials: design and implementation (English)

1 reference

polycystic kidney disease

28 July 2017

1 reference

J Philip Miller

6

0 references

Robert William Schrier

16

object named as

Robert W Schrier

1 reference

28 July 2017

7

Dana C Miskulin

1 reference

28 July 2017

Arlene B Chapman

1

1 reference

28 July 2017

Vicente E Torres

2

1 reference

28 July 2017

Ronald D Perrone

3

1 reference

28 July 2017

Theodore I Steinman

4

1 reference

28 July 2017

Kyongtae T Bae

5

1 reference

28 July 2017

Frederic Rahbari Oskoui

8

1 reference

28 July 2017

Amirali Masoumi

9

1 reference

28 July 2017

Marie C Hogan

10

1 reference

28 July 2017

Franz T Winklhofer

11

1 reference

28 July 2017

William Braun

12

1 reference

28 July 2017

Paul A Thompson

13

1 reference

28 July 2017

Catherine M Meyers

14

1 reference

28 July 2017

Cass Kelleher

15

1 reference

28 July 2017

1 January 2010

1 reference

Clinical Journal of the American Society of Nephrology

28 July 2017

1 reference

28 July 2017

5

1 reference

28 July 2017

1

1 reference

28 July 2017

102-109

1 reference

Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Random-effects models for longitudinal data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Creatinine excretion as a measure of protein nutrition in adults of varying age.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Changing frequency of interim analysis in sequential monitoring

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

No effect of enalapril on progression in autosomal dominant polycystic kidney disease

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801653

Prognosis of adult onset polycystic kidney disease re-evaluated

31 October 2018

1 reference

12 December 2020

Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

The COOPERATE trial: a letter of concern

1 reference

12 December 2020

The power to detect differences in average rates of change in longitudinal studies

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients

1 reference

12 December 2020

Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease

1 reference

12 December 2020

ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk?

1 reference

12 December 2020

Volume progression in polycystic kidney disease

1 reference

12 December 2020

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

12 December 2020

Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

The diagnosis and prognosis of autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.04310709

1 reference

28 July 2017

1 reference

28 July 2017

1 reference